Webster Bailey Buys Shares in PVCT
Webster Bailey purchased 48,917 shares of PVCT on June 30, 2026.
Key Points
- Webster Bailey purchased 48,917 shares of PVCT on June 30, 2026, with shares trading near $0.07 Wednesday.
- PVCT shares have seen activity from several institutional investors, with Atlas Wealth LLC opening a new position of 19,620 shares.
- Multiple insiders, including CEO Edward Pershing, have been active in buying PVCT shares recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Webster Bailey recently bought 48,917 shares of PVCT on June 30, 2026. The shares were acquired in a transaction not planned under a Rule 10b5-1 trading plan. On Wednesday, shares of PVCT traded near $0.07.
Other Institutional Activity in PVCT
Several institutional investors have shown interest in PVCT. Atlas Wealth LLC opened a new position with 19,620 shares valued at about $999. Meanwhile, other funds like Home Federal Bank of Tennessee and Wealth Preservation Advisors, LLC maintained their positions, holding 100,000 shares valued at $5,100 and 52,600 shares valued at $2,677, respectively.
Insider Buying and Selling at Provectus Biopharmaceuticals, Inc.
In addition to Webster Bailey, other insiders have also been active in acquiring PVCT shares. On June 30, 2026, Lacey John III and Dominic Rodrigues, President of PVCT, each purchased 48,917 and 45,860 shares, respectively. Earlier in the month, on June 5, CEO Edward Pershing bought 9,436 shares and also sold the same amount on the same day. Additionally, on May 28, Pershing acquired another 5,242 shares.
Bottom Line
Webster Bailey's purchase of PVCT shares is part of a broader trend of insider buying at the company. Investors often track such activity for potential insights into the company's prospects. However, it's important to remember that insider transactions are just one piece of the puzzle. As always, these filings reflect past actions and may not indicate current holdings or future intentions.
Get Provectus Biopharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PVCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.